Please use this identifier to cite or link to this item:
|Title:||Brain amyloid imaging.||Austin Authors:||Rowe, Christopher ;Villemagne, Victor||Affiliation:||Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia||Issue Date:||8-Feb-2013||Publication information:||Journal of Nuclear Medicine Technology 2013; 41(1): 11-8||Abstract:||Imaging of brain β-amyloid plaques with (18)F-labeled tracers for PET will likely be available in clinical practice to assist the diagnosis of Alzheimer disease (AD). With the rapidly growing prevalence of AD as the population ages, and the increasing emphasis on early diagnosis and treatment, brain amyloid imaging is set to become a widely performed investigation. All physicians reading PET scans will need to know the complex relationship between amyloid and cognitive decline, how to best acquire and display images for detection of amyloid, and how to recognize the patterns of tracer binding in AD and other causes of dementia. This article will provide nuclear medicine physicians with the background knowledge required for understanding this emerging investigation, including its appropriate use, and prepare them for practical training in scan interpretation.||URI:||http://ahro.austin.org.au/austinjspui/handle/1/11670||DOI:||10.2967/jnumed.110.076315||URL:||https://pubmed.ncbi.nlm.nih.gov/23396994||Type:||Journal Article||Subjects:||Alzheimer Disease.diagnosis.metabolism.pathology
|Appears in Collections:||Journal articles|
Show full item record
checked on Nov 28, 2022
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.